Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Retinal

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    631 result(s) found for: Retinal. Displaying page 7 of 32.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2014-001351-23 Sponsor Protocol Number: EGT022-01 Start Date*: 2017-08-15
    Sponsor Name:EyeGene, Inc
    Full Title: A phase IIa, randomized, placebo-controlled, double-blind, parallel study to investigate the efficacy of EG-Mirotin subcutaneously administered in multiple doses on diabetic macular edema in diabet...
    Medical condition: diabetic retinopathy patients having early diabetic macular edema (DME)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10012689 Diabetic retinopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-000754-97 Sponsor Protocol Number: OP/2017/6195 Start Date*: 2020-10-23
    Sponsor Name:University Hospitals Bristol and Weston NHS Foundation Trust
    Full Title: Adalimumab vs placebo as add-on to Standard Therapy for autoimmune Uveitis: Tolerability, Effectiveness and cost-effectiveness: a randomized controlled trial.
    Medical condition: Autoimmune non-infectious uveitis (ANIU)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10075690 Autoimmune uveitis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-004758-27 Sponsor Protocol Number: V1 Start Date*: 2013-01-30
    Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Augenheilkunde
    Full Title: fMRI analysis of the visual cortex in neovascular age-related macular degeneration
    Medical condition: 20 patients with neovascular age-related macular degeneration will be examined before and after 3 monthly administered intravitreal ranibizumab injections according to the label with 7 tesla magnet...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004769-15 Sponsor Protocol Number: V1.2 Start Date*: 2013-12-13
    Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Augenheilkunde
    Full Title: fMRI analysis of the visual cortex in neovascular Age-related Macular Degeneration
    Medical condition: 20 patients with neovascular age-related macular degeneration will be examined before and after 3 monthly administered intravitreal ranibizumab injections according to the label with 3 tesla magnet...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2013-003640-23 Sponsor Protocol Number: ECR-RET-2013-05 Start Date*: 2014-01-13
    Sponsor Name:AIBILI - Association for Innovation and Biomedical Research on Light and Image
    Full Title: Prospective, randomized, multicentre, open label, phase II / III study to assess efficacy and safety of ranibizumab 0.5 mg intravitreal injections plus panretinal photocoagulation (PRP) versus PRP ...
    Medical condition: Patients with type I or type II diabetes mellitus and high risk diabetic retinopathy.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004853 10036857 Proliferative diabetic retinopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2004-005197-23 Sponsor Protocol Number: 1/1 Start Date*: 2005-10-06
    Sponsor Name:Klinik und Poliklinik für Augenheilkunde der Universität Regensburg
    Full Title: Funktionelle Ergebnisse der intravitrealen Injektion von Triamcinolonacetonid im Vergleich zur konventionellen Lasertherapie bei diabetischem Makulaödem.
    Medical condition: Patients with diffuse macular edema due to diabetic retinopathy and decrease in visual acuity.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002431-15 Sponsor Protocol Number: CRFB002ADE23 Start Date*: 2013-10-09
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 12-month, phase IV, randomized, open label, multicenter study to compare efficacy of 0.5 mg ranibizumab PRN compared to 2 mg aflibercept bimonthly intravitreal injections on retinal thickness sta...
    Medical condition: Visual impairment due to neovascular AMD
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) NO (Completed) AT (Completed) DK (Completed) BE (Completed) NL (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003104-42 Sponsor Protocol Number: NSR-CHM-OS2(273CH201) Start Date*: 2018-01-05
    Sponsor Name:NightstaRx Ltd (A Biogen Company)
    Full Title: A Long-term Follow-up Study to Evaluate the Safety and Efficacy of Retinal Gene Therapy in Subjects with Choroideremia Previously Treated with Adeno-Associated Viral Vector Encoding Rab Escort Prot...
    Medical condition: Choroideremia (CHM) X-Linked Retinitis Pigmentosa (XLRP)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10008791 Choroideremia LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10038914 Retinitis pigmentosa PT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Trial now transitioned) GB (GB - no longer in EU/EEA) FI (Completed) FR (Trial now transitioned) DK (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002873-88 Sponsor Protocol Number: MGT-RPGR-021 Start Date*: 2022-07-19
    Sponsor Name:MeiraGTx UK II Limited
    Full Title: Phase 3 Randomized, Controlled Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated with Variants in the RPGR gene
    Medical condition: X-Linked Retinitis Pigmentosa caused by mutations in the RPGR gene
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10038914 Retinitis pigmentosa PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IE (Completed) NL (Ongoing) BE (Completed) ES (Ongoing) FR (Completed) DK (Completed) DE (Prematurely Ended) IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-005082-64 Sponsor Protocol Number: 039/SI Start Date*: 2008-10-13
    Sponsor Name:SIFI
    Full Title: EVALUATION OF THE EFFICACY AND SAFETY OF A NEW STEROID-ANTIBIOTIC OPHTHALMIC GEL AS ANTI-INFLAMMATORY AND ANTIMICROBIAL TOPICAL TREATMENT FOLLOWING MICROINCISIONAL VITREO-RETINAL SURGERY.
    Medical condition: Ocular inflammation following microincisional vitreo-retinal surgery
    Disease: Version SOC Term Classification Code Term Level
    9.1 10054364 Conjunctival hyperemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022616-39 Sponsor Protocol Number: CRFB002DGB14 Start Date*: 2010-11-30
    Sponsor Name:Novartis Pharmaceuticals UK Ltd
    Full Title: RELIGHT - Ranibizumab treatment of diabetic macular oEdema with bimonthLy monItorinG after a pHase of initial Treatment. A UK, 18-month, prospective, open-label, multicenter, single-arm Phase IIIb ...
    Medical condition: Diabetic Macular Oedema
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-014854-14 Sponsor Protocol Number: CRFB002AGB10 Start Date*: 2009-11-17
    Sponsor Name:Novartis Pharmaceuticals UK Ltd
    Full Title: A phase II, open-label, multicentre, 12 month study to evaluate the efficacy and safety of ranibizumab (0.5 mg) in patients with choroidal neovascularization secondary to pathological myopia (PM)
    Medical condition: Choroidal neovascularisation (CNV) secondary to pathological myopia (PM)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10015919 - Eye disorders 10060823 Choroidal neovascularisation PT
    13.1 10015919 - Eye disorders 10067128 Myopic retinal degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-014409-15 Sponsor Protocol Number: CRFB002DPT04T Start Date*: 2010-01-08
    Sponsor Name:AIBILI - Association for Innovation and Biomedical Research on Light and Image
    Full Title: Prospective, randomized, multicenter, open label phase II study to access efficacy and safety of Lucentis monotherapy (ranibizumab 0.5 mg intravitreal injections) compared with Lucentis plus panret...
    Medical condition: Proliferative Diabetic Retinopathy.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10036857 Proliferative diabetic retinopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000300-10 Sponsor Protocol Number: IDI-AFLI-2013-01 Start Date*: 2014-04-23
    Sponsor Name:Fundació Instituto de Investigación Biomédica de Bellvitge (Fundació IDIBELL)
    Full Title: Phase IV study to evaluate the efficacy of aflibercept in naive patients with retinal angiomatous proliferation (RAP) lesions on an individualized ?Treat and Extend? (TAE) regimen. AFLIRAP Study.
    Medical condition: Retinal angiomatous proliferation lesions (RAP)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016158-42 Sponsor Protocol Number: IT-04-1-8-09 Start Date*: 2009-12-23
    Sponsor Name:U.L.S.S. 16
    Full Title: Efficacy of intravitreal bevacizumab for exudative age-related macular degeneration.
    Medical condition: Exudative age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    12.1 10015902 Exudative senile macular degeneration of retina LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-016760-36 Sponsor Protocol Number: CC-02-2009 Start Date*: 2010-02-05
    Sponsor Name:AIBILI
    Full Title: Prospective, randomized, open label phase II study to assess efficacy and safety of Macugen® (pegaptanib 0.3 mg intravitreal injections) plus panretinal photocoagulation (PRP) and PRP (monotherapy)...
    Medical condition: Proliferative Diabetic Retinopathy.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10036857 Proliferative diabetic retinopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003041-10 Sponsor Protocol Number: CRFB002H2301 Start Date*: 2015-04-14
    Sponsor Name:NOVARTIS FARMA S.p.A.
    Full Title: RAINBOW study: a randomized, controlled study evaluating the efficacy and safety of RAnibizumab compared with laser therapy for the treatment of INfants BOrn prematurely With retinopathy of prematu...
    Medical condition: Retinopathy of prematurity (ROP)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10015919 - Eye disorders 10038933 Retinopathy of prematurity PT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) EE (Completed) LT (Completed) HU (Completed) BE (Completed) AT (Completed) DE (Completed) GB (Completed) HR (Completed) FR (Completed) SK (Completed) CZ (Completed) GR (Completed) DK (Completed) FI (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-023923-78 Sponsor Protocol Number: FH-1.3 Start Date*: 2011-03-30
    Sponsor Name:Forsight Vision 4, Inc.
    Full Title: “ A prospective clinical trial to evaluate the V4 Drug delivery device for long term delivery of Ranibizumab for the Treatment of Choroidal Neovascularization”
    Medical condition: Choroidal Neovascularization (CNV) secondary to Age-related Macular Degeneration (AMD) is among the leading causes of blindness in the world. The primary treatment modality is injection of Lucentis...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003955-23 Sponsor Protocol Number: DR2 Start Date*: 2016-04-15
    Sponsor Name:Dept. of Ophthalmology, Rigshospitalet – Glostrup
    Full Title: Diabetic retinopathy: Effects of melatonin treatment on visual functions and circadian rhythm.
    Medical condition: Diabetic Retinopathy and Sleep disorder
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10012689 Diabetic retinopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-018619-14 Sponsor Protocol Number: Lira-Vasc-001 Start Date*: 2010-03-31
    Sponsor Name:ikfe GmbH
    Full Title: Impact of Liraglutide on Endothelial Function and Microvascular Blood Flow in Type 2 Diabetes Mellitus
    Medical condition: Type 2 Diabetes Mellitus
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 00:31:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA